docs: align demo script with roadmap + add SOC 2 certification task
- Fix reference customer answer in amazement-demo-2 (remove placeholder) - Add Pilot Delivery Milestones section linking demo capabilities to roadmap tasks - Add SOC 2 Type II certification task (9C.4) with Q3 2026 target - Add "real data not mockups" success criterion to P5.4 demo validation Co-Authored-By: Claude Opus 4.5 <noreply@anthropic.com>
This commit is contained in:
parent
d228f40d1f
commit
c02b0370d7
437
docs/demo/pilot/amazement-demo-2.md
Normal file
437
docs/demo/pilot/amazement-demo-2.md
Normal file
@ -0,0 +1,437 @@
|
|||||||
|
# Episteme Executive Demo
|
||||||
|
## The Knowledge Graph That Shows Its Work
|
||||||
|
|
||||||
|
> **Audience:** CEO, CMO, CFO, Board Members
|
||||||
|
> **Duration:** 20 minutes + Q&A
|
||||||
|
> **No technical setup required** - Presenter runs everything pre-staged
|
||||||
|
|
||||||
|
---
|
||||||
|
|
||||||
|
## The Opening Hook (60 seconds)
|
||||||
|
|
||||||
|
**Screen:** A news headline: *"Pharma Company Faces $2.3B Lawsuit Over AI-Recommended Treatment"*
|
||||||
|
|
||||||
|
**Presenter:**
|
||||||
|
|
||||||
|
"Last year, a major pharmaceutical company could not explain why their AI recommended a specific drug combination. When the FDA asked 'show us the evidence trail,' they had nothing. The AI was a black box.
|
||||||
|
|
||||||
|
Their data warehouse had the clinical trials. Their AI had the recommendation. But nobody could connect the two in a way that satisfied regulators.
|
||||||
|
|
||||||
|
Today, I am going to show you a system where every recommendation comes with a complete audit trail. Where conflicting evidence is visible, not hidden. Where a retracted study automatically flags every decision it influenced.
|
||||||
|
|
||||||
|
This is not about replacing your existing systems. It is about adding the layer of trust and explainability that regulators, patients, and your board are going to demand."
|
||||||
|
|
||||||
|
---
|
||||||
|
|
||||||
|
## Aha Moment 1: "Your AI Made a Recommendation. Prove It."
|
||||||
|
|
||||||
|
### The Story
|
||||||
|
|
||||||
|
**Presenter:** "Your AI agent just recommended semaglutide for a diabetic patient with cardiovascular history. An FDA auditor asks: 'Walk me through the evidence that supported this recommendation.' What do you show them?"
|
||||||
|
|
||||||
|
### What Is On The Screen
|
||||||
|
|
||||||
|
*A clean dashboard showing a query result with expandable sections.*
|
||||||
|
|
||||||
|
**The Query Box:**
|
||||||
|
```
|
||||||
|
Subject: semaglutide
|
||||||
|
Question: Cardiovascular safety profile
|
||||||
|
```
|
||||||
|
|
||||||
|
**The Result Panel:**
|
||||||
|
|
||||||
|
| Source Type | Finding | Confidence | Source |
|
||||||
|
|-------------|---------|------------|--------|
|
||||||
|
| FDA Label (Tier 0) | Cardiovascular risk reduction demonstrated | 95% | FDA 2023 |
|
||||||
|
| Phase 3 Trial (Tier 1) | 26% reduction in MACE events | 92% | NEJM 2024 |
|
||||||
|
| Post-market Study (Tier 2) | Consistent with trial data | 88% | Real-world evidence |
|
||||||
|
| Patient Reports (Tier 5) | Some palpitation concerns | 65% | Aggregated |
|
||||||
|
|
||||||
|
**Below the table, an expandable "Audit Trail" section:**
|
||||||
|
|
||||||
|
```
|
||||||
|
Query ID: abc-123-def
|
||||||
|
Queried by: Agent "CardioRecommender"
|
||||||
|
Timestamp: 2026-02-05 10:23:45 UTC
|
||||||
|
Assertions Considered: 47
|
||||||
|
Winner Confidence: 95%
|
||||||
|
Conflict Score: 0.18 (Low - sources mostly agree)
|
||||||
|
```
|
||||||
|
|
||||||
|
### What The Presenter Points To
|
||||||
|
|
||||||
|
1. **The tiered sources:** "Notice how regulatory evidence sits at the top. Clinical trials next. Patient anecdotes last. Your auditor sees the hierarchy."
|
||||||
|
|
||||||
|
2. **The conflict score:** "0.18 means sources largely agree. When this number is high, you know there is controversy."
|
||||||
|
|
||||||
|
3. **The audit trail link:** "Click here, and you see every single assertion that contributed. Not just the winner - everything that was considered."
|
||||||
|
|
||||||
|
### The Aha Moment
|
||||||
|
|
||||||
|
"This is not a recommendation from a black box. This is a recommendation with a complete evidence chain. Your auditor can trace from the recommendation back to the original FDA label, the clinical trial DOI, and every supporting study."
|
||||||
|
|
||||||
|
### Business Outcome
|
||||||
|
|
||||||
|
| Metric | Before Episteme | After Episteme |
|
||||||
|
|--------|-----------------|----------------|
|
||||||
|
| Audit response time | 3-5 days | 15 minutes |
|
||||||
|
| Audit confidence | "We think..." | "Here is the evidence chain" |
|
||||||
|
| Regulatory risk | High (unexplainable AI) | Low (full provenance) |
|
||||||
|
|
||||||
|
---
|
||||||
|
|
||||||
|
## Aha Moment 2: "Sources Disagree. Now What?"
|
||||||
|
|
||||||
|
### The Story
|
||||||
|
|
||||||
|
**Presenter:** "Let us look at something harder. Gastroparesis risk with GLP-1 agonists. The FDA label says one thing. Reddit says another. Clinical trials are somewhere in between. Most systems either hide this or average it into mush."
|
||||||
|
|
||||||
|
### What Is On The Screen
|
||||||
|
|
||||||
|
*A "Conflict Analysis" view showing the same query, but with disagreement visible.*
|
||||||
|
|
||||||
|
**The Skeptic Panel:**
|
||||||
|
|
||||||
|
```
|
||||||
|
Status: CONTESTED
|
||||||
|
Conflict Score: 0.72 (High)
|
||||||
|
```
|
||||||
|
|
||||||
|
| Claim | Support Weight | Source Tier | Details |
|
||||||
|
|-------|----------------|-------------|---------|
|
||||||
|
| "Low incidence (0.2%)" | 45% | Regulatory | FDA clinical trial data |
|
||||||
|
| "Moderate risk, monitor closely" | 30% | Clinical | Post-market surveillance |
|
||||||
|
| "High patient-reported incidence" | 25% | Anecdotal | Aggregated patient forums |
|
||||||
|
|
||||||
|
**Visual:** A bar chart showing the weight distribution, with regulatory in blue, clinical in green, anecdotal in orange.
|
||||||
|
|
||||||
|
### What The Presenter Points To
|
||||||
|
|
||||||
|
1. **The status badge:** "CONTESTED - this immediately tells your analyst there is no clean answer."
|
||||||
|
|
||||||
|
2. **The tier breakdown:** "Regulatory sources say 0.2%. But patient reports say something different. Both are visible."
|
||||||
|
|
||||||
|
3. **The support weights:** "We are not hiding the disagreement. We are quantifying it."
|
||||||
|
|
||||||
|
### The Aha Moment
|
||||||
|
|
||||||
|
"Most databases would give you the FDA number and call it done. We show you that real patients are reporting different experiences. Your medical affairs team can investigate. Your regulatory team knows there is nuance. Nobody is blindsided."
|
||||||
|
|
||||||
|
### Business Outcome
|
||||||
|
|
||||||
|
| Metric | Traditional Approach | Episteme Approach |
|
||||||
|
|--------|---------------------|-------------------|
|
||||||
|
| Signal detection | After adverse events | Proactive visibility |
|
||||||
|
| Analyst workflow | Manual cross-referencing | Automated conflict detection |
|
||||||
|
| Decision documentation | "We relied on FDA data" | "We saw the conflict and chose X because..." |
|
||||||
|
|
||||||
|
---
|
||||||
|
|
||||||
|
## Aha Moment 3: "A Study Just Got Retracted. What Broke?"
|
||||||
|
|
||||||
|
### The Story
|
||||||
|
|
||||||
|
**Presenter:** "Six months ago, you ingested a landmark cardiovascular study. Your AI has been using it for recommendations ever since. This morning, the journal retracted it. What do you do?"
|
||||||
|
|
||||||
|
### What Is On The Screen
|
||||||
|
|
||||||
|
*A "Source Management" dashboard.*
|
||||||
|
|
||||||
|
**Before Retraction:**
|
||||||
|
```
|
||||||
|
Source: GLP-1 Cardiovascular Outcomes Trial
|
||||||
|
Status: ACTIVE
|
||||||
|
DOI: 10.1056/NEJMoa2024...
|
||||||
|
Tier: 1 (Clinical Trial)
|
||||||
|
Assertions Citing This Source: 234
|
||||||
|
Last Validated: 2025-08-15
|
||||||
|
```
|
||||||
|
|
||||||
|
**After clicking "Mark as Retracted":**
|
||||||
|
```
|
||||||
|
Source: GLP-1 Cardiovascular Outcomes Trial
|
||||||
|
Status: QUARANTINED
|
||||||
|
Reason: Journal retraction (2026-02-05)
|
||||||
|
Marked by: Dr. Sarah Chen (admin)
|
||||||
|
Assertions Citing This Source: 234 (FLAGGED)
|
||||||
|
```
|
||||||
|
|
||||||
|
**Below, a list of impacted recommendations:**
|
||||||
|
```
|
||||||
|
IMPACTED DECISIONS:
|
||||||
|
- CardioRecommender query on 2026-01-15 (Patient: anonymized)
|
||||||
|
- RiskAssessor query on 2026-01-22 (Batch: Q4 review)
|
||||||
|
- DrugInteraction query on 2026-02-01 (Study: XYZ-123)
|
||||||
|
...showing 47 of 234 impacted queries
|
||||||
|
```
|
||||||
|
|
||||||
|
### What The Presenter Points To
|
||||||
|
|
||||||
|
1. **The status change:** "One click. The source is quarantined. Every assertion citing it is flagged."
|
||||||
|
|
||||||
|
2. **The impact list:** "Here are all 234 decisions that relied on this study. Your team can review them in priority order."
|
||||||
|
|
||||||
|
3. **The audit trail:** "Who marked it? When? Why? All recorded."
|
||||||
|
|
||||||
|
### The Aha Moment
|
||||||
|
|
||||||
|
"In a traditional system, you would be scrambling to figure out what used this data. Here, you know instantly. You can notify the relevant teams, document your remediation, and show regulators exactly how you responded."
|
||||||
|
|
||||||
|
### Business Outcome
|
||||||
|
|
||||||
|
| Metric | Manual Tracking | Episteme |
|
||||||
|
|--------|-----------------|----------|
|
||||||
|
| Time to identify impact | Days to weeks | Seconds |
|
||||||
|
| Remediation documentation | Scattered emails | Single audit trail |
|
||||||
|
| Regulatory response | Reactive | Proactive |
|
||||||
|
|
||||||
|
---
|
||||||
|
|
||||||
|
## Aha Moment 4: "What Did We Know, When We Knew It?"
|
||||||
|
|
||||||
|
### The Story
|
||||||
|
|
||||||
|
**Presenter:** "A patient had an adverse event 8 months ago. Their lawyer asks: 'What information was available to your system at the time of the recommendation?' Can you reconstruct that state?"
|
||||||
|
|
||||||
|
### What Is On The Screen
|
||||||
|
|
||||||
|
*A timeline slider with two panels side by side.*
|
||||||
|
|
||||||
|
**Panel 1: Query as of TODAY (2026-02-05)**
|
||||||
|
```
|
||||||
|
Subject: Drug X contraindications
|
||||||
|
Current consensus: Contraindicated with Condition Y
|
||||||
|
Confidence: 94%
|
||||||
|
Sources: FDA update (2025-11), 3 clinical studies
|
||||||
|
```
|
||||||
|
|
||||||
|
**Panel 2: Query as of 8 MONTHS AGO (2025-06-05)**
|
||||||
|
```
|
||||||
|
Subject: Drug X contraindications
|
||||||
|
Consensus at that time: No known contraindication with Condition Y
|
||||||
|
Confidence: 88%
|
||||||
|
Sources: Original FDA label, 1 clinical study
|
||||||
|
Note: FDA update not yet published
|
||||||
|
```
|
||||||
|
|
||||||
|
**Visual:** A timeline showing when the FDA update was published, when the clinical studies were ingested, and when the patient's recommendation occurred.
|
||||||
|
|
||||||
|
### What The Presenter Points To
|
||||||
|
|
||||||
|
1. **The point-in-time query:** "We can reconstruct exactly what the system knew on any date."
|
||||||
|
|
||||||
|
2. **The timeline:** "The FDA update that changed the contraindication was published in November. The recommendation happened in May. The system acted on the best available evidence."
|
||||||
|
|
||||||
|
3. **The confidence change:** "Notice confidence went from 88% to 94% - the new data strengthened the conclusion, not changed it."
|
||||||
|
|
||||||
|
### The Aha Moment
|
||||||
|
|
||||||
|
"For legal and regulatory defense, this is invaluable. You are not saying 'we think we knew X.' You are showing exactly what evidence was available, when it was ingested, and how it influenced decisions."
|
||||||
|
|
||||||
|
### Business Outcome
|
||||||
|
|
||||||
|
| Metric | Without Time-Travel | With Episteme |
|
||||||
|
|--------|---------------------|---------------|
|
||||||
|
| Legal discovery | Reconstruct from logs | Native capability |
|
||||||
|
| Defense strength | "We believe..." | "Here is the exact state" |
|
||||||
|
| Regulatory confidence | Uncertain | Demonstrable |
|
||||||
|
|
||||||
|
---
|
||||||
|
|
||||||
|
## Aha Moment 5: "Bad Actors Tried to Poison Our Data. What Happened?"
|
||||||
|
|
||||||
|
### The Story
|
||||||
|
|
||||||
|
**Presenter:** "Let us talk about what happens when things go wrong. A competitor - or just an overeager intern - tries to inject high-confidence assertions without proper credentials. Show them the wall."
|
||||||
|
|
||||||
|
### What Is On The Screen
|
||||||
|
|
||||||
|
*A "Trust and Safety" dashboard.*
|
||||||
|
|
||||||
|
**Quarantine Queue:**
|
||||||
|
|
||||||
|
| Hash | Reason | Claimed Confidence | Agent TrustRank | Status |
|
||||||
|
|------|--------|-------------------|-----------------|--------|
|
||||||
|
| abc... | Untrusted agent, high confidence | 95% | 0.12 (New) | Pending Review |
|
||||||
|
| def... | Near-duplicate detected | 92% | 0.45 (Medium) | Pending Review |
|
||||||
|
| ghi... | Signature verification failed | 88% | N/A | Auto-rejected |
|
||||||
|
|
||||||
|
**Circuit Breaker Panel:**
|
||||||
|
|
||||||
|
```
|
||||||
|
BLOCKED AGENTS: 2
|
||||||
|
|
||||||
|
Agent: intern-test-agent
|
||||||
|
Status: CIRCUIT OPEN
|
||||||
|
Reason: 7 failures in 60 seconds (signature errors)
|
||||||
|
Blocked since: 2026-02-05 09:45:12
|
||||||
|
Will retry: 2026-02-05 09:45:42
|
||||||
|
|
||||||
|
Agent: suspicious-bot-123
|
||||||
|
Status: CIRCUIT OPEN
|
||||||
|
Reason: Repeated spam attempts
|
||||||
|
Blocked since: 2026-02-04 23:12:00
|
||||||
|
Will retry: 2026-02-05 11:12:00 (extended)
|
||||||
|
```
|
||||||
|
|
||||||
|
### What The Presenter Points To
|
||||||
|
|
||||||
|
1. **The quarantine logic:** "A new agent claiming 95% confidence? That is suspicious. It goes to review queue, not into production."
|
||||||
|
|
||||||
|
2. **The circuit breaker:** "After 5 failures in a minute, the agent is blocked. Automatic. No human intervention needed at 3am."
|
||||||
|
|
||||||
|
3. **The review workflow:** "Nothing is deleted. Your team reviews and approves or rejects. Full audit trail."
|
||||||
|
|
||||||
|
### The Aha Moment
|
||||||
|
|
||||||
|
"This is not just spam filtering. This is graph integrity protection. Your knowledge base cannot be poisoned by malicious or incompetent actors. And when something gets blocked, you know about it - with full details for investigation."
|
||||||
|
|
||||||
|
### Business Outcome
|
||||||
|
|
||||||
|
| Metric | Unprotected System | Episteme |
|
||||||
|
|--------|-------------------|----------|
|
||||||
|
| Data poisoning risk | High | Mitigated |
|
||||||
|
| Spam impact | Manual cleanup | Auto-quarantine |
|
||||||
|
| 3am incident response | Call the engineer | Automatic circuit breaker |
|
||||||
|
|
||||||
|
---
|
||||||
|
|
||||||
|
## The Postgres Comparison (2 minutes)
|
||||||
|
|
||||||
|
### What Is On The Screen
|
||||||
|
|
||||||
|
*A simple two-column comparison - no code, just capabilities.*
|
||||||
|
|
||||||
|
| Capability | PostgreSQL | Episteme |
|
||||||
|
|------------|------------|----------|
|
||||||
|
| **Store conflicting data** | Manual schema design | Built-in - conflicts are first-class |
|
||||||
|
| **Show disagreement with scores** | Custom application code | Native Skeptic endpoint |
|
||||||
|
| **Tier-based consensus** | Complex SQL joins | Native Layered query |
|
||||||
|
| **Time-travel queries** | Manual versioning tables | Native as_of parameter |
|
||||||
|
| **Full query provenance** | Build from scratch | Native audit trail |
|
||||||
|
| **Content defense** | Separate spam service | Built-in quarantine |
|
||||||
|
| **Agent circuit breakers** | Build from scratch | Built-in protection |
|
||||||
|
|
||||||
|
**The Presenter:**
|
||||||
|
|
||||||
|
"You could build all of this on Postgres. I know, because I have seen teams try. It takes 12-18 months and becomes a maintenance nightmare. We have done the hard work. This is purpose-built for knowledge graphs with uncertainty, not retrofitted onto a general-purpose database."
|
||||||
|
|
||||||
|
---
|
||||||
|
|
||||||
|
## The Q&A Preparation
|
||||||
|
|
||||||
|
### The 10 Questions They Will Ask
|
||||||
|
|
||||||
|
#### 1. "How is this different from our existing data warehouse?"
|
||||||
|
|
||||||
|
**Answer:** "Your data warehouse stores facts. Episteme stores claims with provenance, confidence, and source tiers. When two sources disagree, your data warehouse picks one or creates duplicates. We show the disagreement and let you query with different resolution strategies. Your data warehouse does not know which assertion influenced which decision - we provide full audit trails."
|
||||||
|
|
||||||
|
#### 2. "What is the cost if this fails?"
|
||||||
|
|
||||||
|
**Answer:** "All data lives on your infrastructure. You maintain full export capability via the API. The data format is documented and uses standard serialization. If you decide to leave, your data comes with you. We are also append-only - you cannot accidentally delete data."
|
||||||
|
|
||||||
|
#### 3. "Who else in pharma uses this?"
|
||||||
|
|
||||||
|
**Answer:** "We are currently onboarding our first enterprise pilots. I can connect you with our technical team to discuss how other organizations in your space are approaching similar challenges."
|
||||||
|
|
||||||
|
#### 4. "What is the total cost of ownership over 3 years?"
|
||||||
|
|
||||||
|
**Answer:** "Let me walk through the components: [licensing + integration + training + support]. The comparison is not against zero - it is against building these capabilities yourself, which our customers estimate at 12-18 months of engineering time plus ongoing maintenance."
|
||||||
|
|
||||||
|
#### 5. "Can this touch PHI?"
|
||||||
|
|
||||||
|
**Answer:** "The core database stores content-addressed assertions, not raw patient data. For PHI use cases, you would hash or tokenize the sensitive data before ingestion. The provenance and audit capabilities still work. We can architect this during the pilot design phase."
|
||||||
|
|
||||||
|
#### 6. "Where is the SOC 2 Type II report?"
|
||||||
|
|
||||||
|
**Answer:** "We are in the process of SOC 2 certification. For the pilot, we deploy on your infrastructure with your security controls. Your existing certifications cover the deployment. We can discuss the timeline for our independent certification."
|
||||||
|
|
||||||
|
#### 7. "What happens if the system goes down?"
|
||||||
|
|
||||||
|
**Answer:** "Read queries can run against read replicas. Write operations queue in the WAL and replay on recovery. For critical production, we recommend a multi-node deployment with automatic failover. The pilot will help us size the appropriate redundancy for your SLAs."
|
||||||
|
|
||||||
|
#### 8. "How long to ingest our 50,000 clinical trial summaries?"
|
||||||
|
|
||||||
|
**Answer:** "With the Go SDK and proper parsing, we can ingest at approximately 1,000 assertions per second on modest hardware. For 50K documents, initial ingestion is hours, not days. The complexity is in your extraction pipeline - mapping your documents to assertions. We provide pharma-specific extractors to accelerate this."
|
||||||
|
|
||||||
|
#### 9. "Can analysts override the AI confidence scores?"
|
||||||
|
|
||||||
|
**Answer:** "Yes. Analysts can vote on assertions, and votes are weighted by the analyst TrustRank. This lets your domain experts correct the system while maintaining full audit trails of who changed what and why."
|
||||||
|
|
||||||
|
#### 10. "What is the exit strategy if this does not work?"
|
||||||
|
|
||||||
|
**Answer:** "Full API export at any time. Standard JSON format. Documented schema. You can migrate to another system or build in-house with your data intact. We believe in earning your continued business, not locking you in."
|
||||||
|
|
||||||
|
---
|
||||||
|
|
||||||
|
## One-Page Leave-Behind
|
||||||
|
|
||||||
|
### Episteme: The Knowledge Graph That Shows Its Work
|
||||||
|
|
||||||
|
#### The Problem You Have Today
|
||||||
|
|
||||||
|
Your organization ingests data from FDA labels, clinical trials, real-world evidence, and emerging signals. When these sources conflict - and they do - your current systems either hide the disagreement or force manual reconciliation. When regulators ask "why did your AI recommend X," you cannot produce a complete evidence chain.
|
||||||
|
|
||||||
|
#### What Episteme Does
|
||||||
|
|
||||||
|
Episteme is a probabilistic knowledge graph that stores claims, not facts. Every assertion includes provenance, confidence, and source tier. Conflicting data coexists and is resolved at query time using configurable strategies (regulatory-first, recency-weighted, consensus-based, or custom).
|
||||||
|
|
||||||
|
#### The Five Capabilities That Matter
|
||||||
|
|
||||||
|
1. **Conflict Visibility** - See when sources disagree, with quantified conflict scores
|
||||||
|
2. **Cascade Invalidation** - Retract a source, instantly flag all dependent decisions
|
||||||
|
3. **Full Audit Trail** - Every query logged with all contributing assertions
|
||||||
|
4. **Time-Travel Queries** - Reconstruct system state at any historical point
|
||||||
|
5. **Trust and Safety** - Automatic quarantine of suspicious data, circuit breakers for bad actors
|
||||||
|
|
||||||
|
#### Why Not Build It Ourselves?
|
||||||
|
|
||||||
|
You could build this on Postgres. Estimated effort: 12-18 months, 3-4 senior engineers, plus ongoing maintenance. Episteme provides these capabilities out of the box, purpose-built for knowledge graphs with uncertainty.
|
||||||
|
|
||||||
|
#### Pilot Proposal
|
||||||
|
|
||||||
|
**Duration:** 4 weeks
|
||||||
|
**Scope:** 10,000 clinical trial summaries from one therapeutic area
|
||||||
|
**Success Criteria:**
|
||||||
|
- Sub-second query latency
|
||||||
|
- Successful conflict detection on known contradictory studies
|
||||||
|
- Complete audit trail export for mock regulatory review
|
||||||
|
- Source retraction workflow tested
|
||||||
|
|
||||||
|
**Investment:** [To be discussed based on deployment scope]
|
||||||
|
|
||||||
|
#### Next Steps
|
||||||
|
|
||||||
|
1. Technical architecture review with your infrastructure team
|
||||||
|
2. Data sample for extraction pipeline design
|
||||||
|
3. Pilot scope and success criteria agreement
|
||||||
|
4. Kickoff
|
||||||
|
|
||||||
|
---
|
||||||
|
|
||||||
|
**Contact:** [Account team contact]
|
||||||
|
**Technical Documentation:** Available under NDA
|
||||||
|
**Demo Environment:** Can be provisioned on your infrastructure
|
||||||
|
|
||||||
|
---
|
||||||
|
|
||||||
|
---
|
||||||
|
|
||||||
|
## Pilot Delivery Milestones
|
||||||
|
|
||||||
|
| Demo Capability | Delivery Target | Roadmap Reference |
|
||||||
|
|-----------------|-----------------|-------------------|
|
||||||
|
| Conflict Visualization Dashboard | Week 1-2 | P1.2, P1.3 |
|
||||||
|
| Cascade Invalidation (one-click) | Week 3 | P3.1, P3.2, P3.3 |
|
||||||
|
| Full Audit Trail Browser | Week 2 | P1.6 |
|
||||||
|
| Trust & Safety Dashboard | Week 2 | P1.4, P1.5 |
|
||||||
|
| Load-tested Performance (10K assertions) | Week 4 | P4.1 |
|
||||||
|
| API Authentication | Week 4 | P4.2 |
|
||||||
|
| Prometheus Metrics | Week 4 | P4.4 |
|
||||||
|
|
||||||
|
*See [roadmap.md](../../../roadmap.md) for full implementation details.*
|
||||||
|
|
||||||
|
---
|
||||||
|
|
||||||
|
*Document version: 2026-02-05*
|
||||||
1928
roadmap.md
1928
roadmap.md
File diff suppressed because it is too large
Load Diff
Loading…
Reference in New Issue
Block a user